KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Issued
Ratios

AbbVie (ABBV) R&D In Process (2016 - 2025)

AbbVie (ABBV) has disclosed R&D In Process for 14 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly R&D In Process fell 9.64% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, up 97.68% year-over-year, with the annual reading at $5.0 billion for FY2025, 81.94% up from the prior year.
  • R&D In Process for Q4 2025 was $1.3 billion at AbbVie, down from $1.9 billion in the prior quarter.
  • The five-year high for R&D In Process was $1.9 billion in Q3 2025, with the low at $40.0 million in Q3 2022.
  • Average R&D In Process over 5 years is $409.5 million, with a median of $249.0 million recorded in 2024.
  • The sharpest move saw R&D In Process tumbled 90.0% in 2022, then skyrocketed 2217.07% in 2025.
  • Over 5 years, R&D In Process stood at $370.0 million in 2021, then tumbled by 34.32% to $243.0 million in 2022, then rose by 16.05% to $282.0 million in 2023, then soared by 396.45% to $1.4 billion in 2024, then fell by 9.64% to $1.3 billion in 2025.
  • According to Business Quant data, R&D In Process over the past three periods came in at $1.3 billion, $1.9 billion, and $335.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.